Targeted in vivo imaging of integrin αvβ6 with an improved radiotracer and its relevance in a pancreatic tumor model

Cancer Research

Volumn 69, Issue 14, 2009, Pages 5843-5850

  Hausner, Sven H ^a   Abbey, Craig K ^b   Bold, Richard J ^c   Gagnon, M Karen ^a   Marik, Jan ^a   Marshall, John F ^d   Stanecki, Cathy E ^a   Sutcliffe, Julie L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA6 INTEGRIN; FLUOROBENZOYL 2 (MACROGOL 28) ASPARAGINYL 20 PHENYLALANYLMETHIONYLASPARTYLVALINE F 18; FLUOROBENZOYLMACROGOL 28 ASPARAGINYL 20 PHENYLALANYLMETHIONYLASPARTYLVALINE F 18; FLUORODEOXYGLUCOSE F 18; MACROGOL DERIVATIVE; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CANCER CELL CULTURE; CANCER MODEL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; HUMAN; HUMAN CELL; MALE; MELANOMA CELL; MOLECULAR IMAGING; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PANCREAS TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIGENS, NEOPLASM; BENZOIC ACIDS; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDIES; FLOW CYTOMETRY; FLUORINE RADIOISOTOPES; FOOT-AND-MOUTH DISEASE VIRUS; HUMANS; INTEGRINS; MALE; MELANOMA, EXPERIMENTAL; MICE; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS; VIRAL PROTEINS;

EID: 67651006249     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4410     Document Type: Article

References (34)

1. Alavi A, Kung JW, Zhuang HM. Implications of PET based molecular imaging on the current and future practice of medicine. Semin Nucl Med 2004;34:56-69.
2. Keogan MT, Tyler D, Clark L, et al. Diagnosis of pancreatic carcinoma: role of FDG PET. Am J Roentgenol 1998;171:1565-70.
3. 18Fluorodeoxyglucose positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg 1999;229:729-38.
4. Czernin J, Allen-Auerbach M, Schelbert HR. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med 2007;48:78S-88S.
5. Heinrich S, Goerres GW, Schäfer M, et al. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 2005;242:235-43.
6. Schöder H, Gönen M. Screening for cancer with PET and PET/CT: potential and limitations. J Nucl Med 2007;48:4S-18S.
7. Blodgett TM, Meltzer CC, Townsend DW. PET/CT: form and function. Radiology 2007;242:360-85.
8. Parsons CM, Sutcliffe JL, Bold RJ. Preoperative evaluation of pancreatic cancer. J Hepato Biliary Pancreatic Surg 2008;15:429-35.
9. 18F-galacto-RGD in cancer patients. J Nucl Med 2005;46:1333-41.
10. 6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest 2005;115:339-47.
11. 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. J Pathol 2007;212:316-24.
12. 6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res 2007;67:5889-95.
13. 6 inhibits tumor progression in vivo by a transforming growth factor-β-regulated mechanism. Cancer Res 2008;68:561-70.
14. v Integrins lead the way for colorectal metastases. Clin Cancer Res 2008;14:6351-3.
15. 6) identified in epithelial cells using the polymerase chain reaction. J Biol Chem 1990;265:11502-7.
16. Breuss JM, Gallo J, Delisser HM, et al. Expression of the β6 integrin subunit in development, neoplasia and tissue-repair suggests a role in epithelial remodeling. J Cell Sci 1995;108:2241-51.
17. Breuss JM, Gillett N, Lu L, Sheppard D, Pytela R. Restricted distribution of integrin h6 messenger-RNA in primate epithelial tissues. J Histochem Cytochem 1993;41:1521-7.
18. 6 integrin in wound healing and cancer of the oral cavity. J Oral Pathol Med 2006;35:1-10.
19. Nemeth JA, Nakada MT, Trikha M, et al. α-v integrins as therapeutic targets in oncology. Cancer Invest 2007;25:632-46.
20. 6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro. Histopathology 2004;45:226-36.
21. 6 acts as a prognostic indicator in gastric carcinoma. Clin Oncol 2008;20:61-6.
22. 6 expression with positron emission tomography. Cancer Res 2007;67:7833-40.
23. Chen EL, Prinz RA. Long-term survival after pancreatic cancer treatment. Am J Surg 2007;194:S127-30.
24. 6 integrin promotes invasion of squamous carcinoma cells through up-regulation of matrix metalloproteinase-9. Int J Cancer 2001;92:641-50.
25. 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR. J Nucl Med 2000;41:429-38.
26. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose - variations with body weight and a method for correction. Radiology 1993;189:847-50.
27. 6 integrin is linked to initiation and progression of periodontal disease. Am J Pathol 2008;172:1271-86.
28. Harris JM, Chess RB. Effect of PEGylation on pharmaceuticals. Nat Rev Drug Discov 2003;2:214-21.
29. Greenwald RB, Choe YH, McGuire J, Conover CD. Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev 2003;55:217-50.
30. Sheppard D. Integrin-mediated activation of latent transforming growth factor β. Cancer Metastasis Rev 2005;24:395-402.
31. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003;2:347-60.
32. 3 targeted radiotracers for tumor imaging. Mol Pharmaceuticals 2006;3:472-87.
33. Delbeke D, Pinson CW. Pancreatic tumors: role of imaging in the diagnosis, staging, and treatment. J Hepato Biliary Pancreatic Surg 2004;11:4-10.
34. Li CW, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007;67:1030-7.